Cargando…
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
AIM: To gain further insights into the efficacy of SAR425899, a dual glucagon‐like peptide‐1/glucagon receptor agonist, by providing direct comparison with the glucagon‐like peptide‐1 receptor agonist, liraglutide, in terms of key outcomes of glucose metabolism. RESEARCH DESIGN AND METHODS: Seventy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359969/ https://www.ncbi.nlm.nih.gov/pubmed/33822469 http://dx.doi.org/10.1111/dom.14394 |
_version_ | 1783737646525186048 |
---|---|
author | Schiavon, Michele Visentin, Roberto Göbel, Britta Riz, Michela Cobelli, Claudio Klabunde, Thomas Dalla Man, Chiara |
author_facet | Schiavon, Michele Visentin, Roberto Göbel, Britta Riz, Michela Cobelli, Claudio Klabunde, Thomas Dalla Man, Chiara |
author_sort | Schiavon, Michele |
collection | PubMed |
description | AIM: To gain further insights into the efficacy of SAR425899, a dual glucagon‐like peptide‐1/glucagon receptor agonist, by providing direct comparison with the glucagon‐like peptide‐1 receptor agonist, liraglutide, in terms of key outcomes of glucose metabolism. RESEARCH DESIGN AND METHODS: Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once‐daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks. Mixed meal tolerance tests were conducted at baseline (BSL) and at the end of treatment (EOT). Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods. RESULTS: From BSL to EOT (median [25th, 75th] percentile), HOMA2 quantified a significant improvement in basal insulin action in liraglutide (35% [21%, 74%]), while secretion enhanced both in SAR425899 (125% [63%, 228%]) and liraglutide (73% [43%, 147%]). OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta‐cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above‐basal beta‐cell responsiveness (139% [64%, 261%] and 69% [−15%, 120%]). A significant delay in glucose absorption was highlighted in SAR425899 (37% [52%,18%]). CONCLUSIONS: SAR425899 and liraglutide improved postprandial glucose control in overweight to obese subjects with T2D. A significantly higher enhancement in beta‐cell function was shown by SAR425899 than liraglutide. |
format | Online Article Text |
id | pubmed-8359969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-83599692021-08-17 Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide Schiavon, Michele Visentin, Roberto Göbel, Britta Riz, Michela Cobelli, Claudio Klabunde, Thomas Dalla Man, Chiara Diabetes Obes Metab Original Articles AIM: To gain further insights into the efficacy of SAR425899, a dual glucagon‐like peptide‐1/glucagon receptor agonist, by providing direct comparison with the glucagon‐like peptide‐1 receptor agonist, liraglutide, in terms of key outcomes of glucose metabolism. RESEARCH DESIGN AND METHODS: Seventy overweight to obese subjects with type 2 diabetes (T2D) were randomized to receive once‐daily subcutaneous administrations of SAR425899 (0.12, 0.16 or 0.20 mg), liraglutide (1.80 mg) or placebo for 26 weeks. Mixed meal tolerance tests were conducted at baseline (BSL) and at the end of treatment (EOT). Metabolic indices of insulin action and secretion were assessed via Homeostasis Model Assessment (HOMA2) and oral minimal model (OMM) methods. RESULTS: From BSL to EOT (median [25th, 75th] percentile), HOMA2 quantified a significant improvement in basal insulin action in liraglutide (35% [21%, 74%]), while secretion enhanced both in SAR425899 (125% [63%, 228%]) and liraglutide (73% [43%, 147%]). OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta‐cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above‐basal beta‐cell responsiveness (139% [64%, 261%] and 69% [−15%, 120%]). A significant delay in glucose absorption was highlighted in SAR425899 (37% [52%,18%]). CONCLUSIONS: SAR425899 and liraglutide improved postprandial glucose control in overweight to obese subjects with T2D. A significantly higher enhancement in beta‐cell function was shown by SAR425899 than liraglutide. Blackwell Publishing Ltd 2021-05-05 2021-08 /pmc/articles/PMC8359969/ /pubmed/33822469 http://dx.doi.org/10.1111/dom.14394 Text en © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Schiavon, Michele Visentin, Roberto Göbel, Britta Riz, Michela Cobelli, Claudio Klabunde, Thomas Dalla Man, Chiara Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title_full | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title_fullStr | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title_full_unstemmed | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title_short | Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide |
title_sort | improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist sar425899 in comparison with liraglutide |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359969/ https://www.ncbi.nlm.nih.gov/pubmed/33822469 http://dx.doi.org/10.1111/dom.14394 |
work_keys_str_mv | AT schiavonmichele improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT visentinroberto improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT gobelbritta improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT rizmichela improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT cobelliclaudio improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT klabundethomas improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide AT dallamanchiara improvedpostprandialglucosemetabolismintype2diabetesbythedualglucagonlikepeptide1glucagonreceptoragonistsar425899incomparisonwithliraglutide |